Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-11-03 00:00:00 ET · period of report 2023-11-01 · accession 0001415889-23-014774 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-03 | 2023-11-01 | JBIO | Verwijs Marinus | CTO | S - Sale | $10.46 | -970 | 0 | -100% | -$10.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-01 | S | D | 970 | $10.46 | 0 | D | — | — | (F2) Includes 970 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.96 to $10.78, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |